Construction of tissue-engineered bone using a bioreactor and platelet-rich plasma

Dong, Weiliang; Jiang, Honglei; Wang, Shuzhen; Li, Huibo; Zhang, Huawu; Zhao, Lei; Peng, Tao; Cao, Zhong; Sun, Shui

doi:10.3892/etm.2014.1774

Cited by 8 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar effect was also demonstrated here in 3D cultures under perfusion flow, since constructs obtained with tPRP‐supplemented culture medium contained, on average, 1.9‐fold more cells than constructs obtained with standard FBS‐supplemented medium after 5 days of culture (Figure C). Cultures of rabbit BMSC in β ‐TCP inside a mostly similar perfusion bioreactor system for 3 weeks were previously reported (Wang et al ., ). However, in that study, no comparison with standard FBS‐supplemented medium was investigated.…”

Section: Discussionmentioning

confidence: 97%

Pooled thrombin-activated platelet-rich plasma: a substitute for fetal bovine serum in the engineering of osteogenic/vasculogenic grafts

Tchang

Pippenger

Todorov

et al. 2015

J Tissue Eng Regen Med

View full text Add to dashboard Cite

The use of fetal bovine serum (FBS) as a culture medium supplement in cell therapy and clinical tissue engineering is challenged by immunological concerns and the risk of disease transmission. Here we tested whether human, thrombin-activated, pooled, platelet-rich plasma (tPRP) can be substituted for FBS in the engineering of osteogenic and vasculogenic grafts, using cells from the stromal vascular fraction (SVF) of human adipose tissue. SVF cells were cultured under perfusion flow into porous hydroxyapatite scaffolds for 5 days, with the medium supplemented with either 10% tPRP or 10% FBS and implanted in an ectopic mouse model. Following in vitro culture, as compared to FBS, the use of tPRP did not modify the fraction of clonogenic cells or the different cell phenotypes, but increased by 1.9-fold the total number of cells. After 8 weeks in vivo, bone tissue was formed more reproducibly and in higher amounts (3.7-fold increase) in constructs cultured with tPRP. Staining for human-specific ALU sequences and for the human isoforms of CD31/CD34 revealed the human origin of the bone, the formation of blood vessels by human vascular progenitors and a higher density of human cells in implants cultured with tPRP. In summary, tPRP supports higher efficiency of bone formation by SVF cells than FBS, likely by enhancing cell expansion in vitro while maintaining vasculogenic properties. The use of tPRP may facilitate the clinical translation of osteogenic grafts with intrinsic capacity for vascularization, based on the use of adipose-derived cells. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

Section: Discussionmentioning

confidence: 97%

Pooled thrombin-activated platelet-rich plasma: a substitute for fetal bovine serum in the engineering of osteogenic/vasculogenic grafts

Tchang

Pippenger

Todorov

et al. 2015

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…PRP has also shown promise as an additive to enhance bone tissue engineering, typically in combination with MSCs. For instance, Wang et al 59 combined bone marrow-derived MSCs with beta-tricalcium phosphate (b-TCP) in a perfusion bioreactor with PRP. They demonstrated enhanced MSC spreading and proliferation on the scaffold after 21 days of culture.…”

Section: In Vitro Studiesmentioning

confidence: 99%

A Systematic Assessment of the Use of Platelet-Rich Plasma in Spinal Fusion

et al. 2015

View full text Add to dashboard Cite

Spinal fusion is one of the most commonly performed procedures for the treatment of spinal instability caused by a multitude of pathologies. However, despite significant advances in spinal instrumentation, failed fusion, or pseudoarthrosis, remains a significant challenge. Therefore, other additives such as bone graft extenders and growth factors have been explored as a method to augment fusion rates. Platelet-rich plasma (PRP) represents an additional approach, as it has shown some promise in bone regeneration. While the general use of PRP in orthopedic applications has been reviewed previously, its use in spinal fusion has not been systematically analyzed. The objective of this review is to systematically discuss the role of PRP in augmentation of bone regeneration for the purpose of spinal fusion. Background information on PRP, including a discussion of its preparation, activation, and growth factors, is included. Additionally, data from in vitro studies utilizing PRP in bone tissue engineering strategies is analyzed, and the available animal and clinical studies are systematically reviewed in order to provide guidance on future research pathways as well as the potential role of PRP in spinal fusion surgery.

show abstract

“…MSC can promote new blood vessels formation and limit the immune reaction [24]. Therefore, the use of human platelet lysate (hPL) as a supplement for MSC culture has demonstrated improvements in cellular proliferation, differentiation and angiogenic properties [25,26]. hPL is a rich source of growth factors like platelet-derived growth factor (PDGF), transforming growth factor (TGF), insulin growth factor (IGF), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) which promote the healing process, angiogenesis and cell osseo-differentiation [25,[27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Adhesion, proliferation and osteogenic differentiation of human MSCs cultured under perfusion with a marine oxygen carrier on an allogenic bone substitute

Pape

Richard

Porchet

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Tissue engineering strategies have been developed to optimize osseointegration in dental implant surgery. One of the major problems is the non-homogeneous spatial cell distribution in the scaffold, as well as subsequent matrix production. Insufficient nutrient and oxygen supplies inside the scaffold are factors in this phenomenon. To mediate this gradient formation, we have implemented a perfusion culture method to seed human bone marrow mesenchymal stem cells (MSCs) into three-dimensional (3-D)-allogenic bone scaffolds in combination with a marine haemoglobin, HEMOXCell, for oxygen delivery. Cell culture was performed under static and perfusion conditions, with standard and osteogenic media, with and without HEMOXCell. The cell seeding efficiency, as well as MSC/scaffold cytocompatibly were assessed using viability and proliferation assays. Scaffolds' cellularization and extracellular matrix (ECM) formation were analyzed using scanning electron microscopy and histological staining. Cell differentiation was investigated with osteogenic biomarkers gene expression analysis. The perfusion culture was observed to significantly promote MSC proliferation and differentiation throughout the scaffolds, especially when using the induction medium w/HEMOXCell. Our data suggest that perfusion culture of MSC into allogenic bone substitute with HEMOXCell as a natural oxygen carrier is promising for tissue engineering applications to oxygenate hypoxic areas and to promote cellular proliferation.

show abstract

Construction of tissue-engineered bone using a bioreactor and platelet-rich plasma

Cited by 8 publications

References 16 publications

Pooled thrombin-activated platelet-rich plasma: a substitute for fetal bovine serum in the engineering of osteogenic/vasculogenic grafts

Pooled thrombin-activated platelet-rich plasma: a substitute for fetal bovine serum in the engineering of osteogenic/vasculogenic grafts

A Systematic Assessment of the Use of Platelet-Rich Plasma in Spinal Fusion

Adhesion, proliferation and osteogenic differentiation of human MSCs cultured under perfusion with a marine oxygen carrier on an allogenic bone substitute

Contact Info

Product

Resources

About